Ontology highlight
ABSTRACT:
SUBMITTER: Sakiyama E
PROVIDER: S-EPMC7152536 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
Sakiyama Emiko E Chinen Yoshiaki Y Tsukamoto Taku T Takimoto-Shimomura Tomoko T Kuwahara-Ota Saeko S Matsumura-Kimoto Yayoi Y Shimura Yuji Y Kobayashi Tsutomu T Horiike Shigeo S Kuroda Junya J
Infection and drug resistance 20200408
Ruxolitinib is a selective JAK1/2 inhibitor that is widely used for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis and polycythemia vera (PV). Despite its clinical efficacy for MPNs, ruxolitinib possesses immunosuppressive properties that potentially increase the risks for opportunistic infection, such as mycobacterium tuberculosis (MTB) infection, and reactivation of occult viral infection. Herein, we report the case of a 76-year-old male with PV who developed tub ...[more]